产业链转型

Search documents
中国经济样本观察·“镇”了不起|“内衣小镇”织出500亿元“里子产业”
Xin Hua Wang· 2025-06-10 07:48
Core Insights - Deep Hu Town in Jinjiang, Fujian Province, produces over 20% of the world's underwear, with an annual output value exceeding 50 billion yuan [1][2] Group 1: Historical Development - Deep Hu Town transitioned from a fishing port to a major underwear production hub over 40 years, starting with home-based workshops making "foreign underwear" [2][3] - The local population recognized the business opportunity in the comfortable materials of "foreign underwear" sent by overseas relatives, leading to a surge in home-based production [2] Group 2: Industry Transformation - The industry evolved from "processing with supplied materials" to a complete industrial chain, including weaving, dyeing, and packaging, significantly reducing costs and increasing profits [3][4] - By the late 1990s, many local entrepreneurs invested in the full supply chain, leading to the establishment of various supporting enterprises and the formation of a comprehensive industry ecosystem [3] Group 3: Operational Efficiency - Deep Hu Town hosts over 500 underwear companies and employs more than 50,000 people, allowing for rapid material sourcing and production [4] - The local industry can assemble all materials for a piece of underwear within half an hour, showcasing its operational efficiency and responsiveness to customer demands [4] Group 4: Product Innovation - The town has developed a range of innovative underwear products with features like cooling, antibacterial, and moisture-wicking properties, expanding beyond basic underwear to include thermal wear and socks [5] - Companies in Deep Hu are increasingly utilizing technology in production, with automated systems enhancing quality and efficiency, reflecting a shift from traditional labor-intensive methods [5]
兄弟科技业绩扭亏为盈大幅增长 药品研发成果渐显成效
Zheng Quan Shi Bao Wang· 2025-04-29 04:17
Core Viewpoint - Brothers Technology (002562) has reported a turnaround in its financial performance for 2024, achieving significant growth and shifting its strategic focus towards a "manufacturing + service" model in key areas such as animal nutrition and human health [1][2] Financial Performance - In 2024, the company achieved total revenue of 3.441 billion yuan, a year-on-year increase of approximately 22% - The net profit attributable to shareholders was 40.81 million yuan, marking a return to profitability - For Q1 2025, total revenue reached 919 million yuan, up 12.1% year-on-year, with a net profit of 20.91 million yuan, also indicating a return to profitability [1] Strategic Focus and Market Position - The company aims to deepen its presence in its core sectors by expanding product applications and extending its existing industrial chain - Brothers Technology's main business includes pharmaceutical food and specialty chemicals, with leading market shares in vitamins and chromium salts, showcasing strong competitive advantages in brand, R&D, quality control, cost management, and marketing [1][2] Growth Drivers - The significant growth in 2024 is attributed to the company's efforts to align with industry policies and development directions, focusing on technological innovation and enhancing the entire industrial chain - The company has seen price increases in some vitamin products, higher sales volumes of vitamins, spices, and chromium salts, and a reduction in inventory costs, contributing to improved profitability [2] Project Developments - Brothers Technology is advancing projects such as the "Phenol Phase II Project" and "Annual Production of 50,000 Tons of Inorganic Chromium Powder," both of which commenced production in the first half of 2024 - The company is also enhancing its channel construction and market expansion to boost production capacity and sales [2] R&D and Product Development - The company is actively pursuing the development of raw materials and formulation products, with successful registrations for iodinated contrast agents and ongoing progress in other pharmaceutical registrations - In March 2025, the company's subsidiary received a drug registration certificate for a specific injection, with other formulation products also advancing through the registration process [3]